- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | FDA sets flu shot recommendations without input of outside advisers | ||
| Fr | Makary advances to full senate vote; Acelyrin, Pliant adopt 'poison pills' | ||
| Do | MeiraGTx spins Parkinson's, obesity gene therapies into AI startup | ||
| Do | Mallinckrodt, Endo to combine in $7B deal | ||
| Mi | Roche broadens obesity drug plans with $1.65B Zealand Pharma deal | ||
| Mi | A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV | ||
| Mi | Flagship startup raises $200M in pursuit of 'scientific superintelligence' | ||
| Mi | Ono pays $280M to license Ionis rare disease drug | ||
| Di | Douglas Kelly, deputy science director at FDA's device center, leaves agency | ||
| Di | Viking inks CordenPharma deal to boost obesity drug supply | ||
| Di | Merck opens $1B vaccine plant in North Carolina | ||
| Di | Arvinas gets positive breast cancer data, but finds differentiation a hard sell | ||
| Di | 2seventy bio, Bluebird's cell therapy spinout, sells to Bristol Myers for less than $300M | ||
| Mo | Beam base editing therapy gets 'proof of concept' in rare lung disease | ||
| Mo | Novo's Wegovy successor disappoints in second large trial | ||
| Mo | Mineralys shares climb on study data for blood pressure drug | ||
| Mo | SynWeave: Revolutionizing biopharma manufacturing by improving titer, timelines and manufacturability | ||
| Mo | 3 ways to accelerate development and de-risk cell and gene therapy manufacturing | ||
| 07.03. | J&J scraps depression testing for potential blockbuster drug | ||
| 07.03. | Walgreens to be acquired in $10B take-private deal | ||
| 07.03. | Roche launches new Boston center; NIH centralizes peer review | ||
| 07.03. | Nimbus swaps CEOs and turns to new leader for 'next chapter' | ||
| 07.03. | Vertex's new pain drug gets first coverage nod from major insurer | ||
| 06.03. | Following FDA cuts, Trump nominee Makary vows 'independent' staff review | ||
| 06.03. | Makary, under review to run FDA, evades pressure to reinstate canceled vaccine meeting |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
